{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:11:37Z","timestamp":1770815497612,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Chondrosarcomas rank as the second most common primary bone malignancy. Characterized by the production of a cartilaginous matrix, these tumors typically exhibit resistance to both radiotherapy (RT) and chemotherapy (CT), resulting in overall poor outcomes: a high rate of mortality, especially among children and adolescents. Due to the considerable resistance to current conventional therapies such as surgery, CT, and RT, there is an urgent need to identify factors contributing to resistance and discover new strategies for optimal treatment. Over the past decade, researchers have delved into the dysregulation of genes associated with tumor development and therapy resistance to identify potential therapeutic targets for overcoming resistance. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including isocitrate dehydrogenase (IDH1\/2) and COL2A1. Molecule-targeting agents and immunotherapies have demonstrated favorable antitumor activity in clinical studies involving patients with advanced chondrosarcomas. In this systematic review, we delineate the clinical features of chondrosarcoma and provide a summary of gene dysregulation and mutation associated with tumor development, as well as targeted therapies as a promising molecular approach. Finally, we analyze the probable role of the tumor microenvironment in chondrosarcoma drug resistance. Methods: A systematic search was conducted across major medical databases (PubMed, Embase, and Cochrane Library) up to 10 November 2023. The search strategy utilized relevant Medical Subject Heading (MeSH) terms and keywords related to \u201cchondrosarcomas\u201d, \u201ctarget therapies\u201d, \u201cimmunotherapies\u201d, and \u201coutcomes\u201d. The studies included in this review consist of randomized controlled trials, non-randomized controlled trials, and cohort studies reporting on the use of target therapies for the treatment of chondrosarcoma in human subjects. Results: Of the initial 279 articles identified, 40 articles were included in the article. The exclusion of 140 articles was due to reasons such as irrelevance, non-reporting of selected results, systematic literature review or meta-analysis, and lack of details on the method\/results. Three tables highlighted clinical studies, preclinical studies, and ongoing clinical trials, encompassing 13, 7, and 20 studies, respectively. For the clinical study, a range of molecular targets, such as death receptors 4\/5 (DR4 and DR5) (15%), platelet-derived growth factor receptor-alpha or -beta (PDGFR-\u03b1, PDGFR-\u03b2) (31%), were investigated. Adverse events were mainly constitutional symptoms emphasizing that to improve therapy tolerance, careful observation and tailored management are essential. Preclinical studies analyzed various molecular targets such as DR4\/5 (28.6%) and COX-2 (28.6%). The prevalent indicator of antitumoral activity was the apoptotic rate of both a single agent (tumor necrosis factor-related apoptosis-inducing ligand: TRAIL) and double agents (TRAIL-DOX, TRAIL-MG132). Ongoing clinical trials, the majority in Phase II (53.9%), highlighted possible therapeutic strategies such as IDH1 inhibitors and PD-1\/PD-L1 inhibitors (30.8%). Conclusions: The present review offers a comprehensive analysis of targeted therapeutics for skull base chondrosarcomas, highlighting a complex landscape characterized by a range of treatment approaches and new opportunities for tailored interventions. The combination of results from molecular research and clinical trials emphasizes the necessity for specialized treatment strategies and the complexity of chondrosarcoma biology.<\/jats:p>","DOI":"10.3390\/jpm14030261","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:59:39Z","timestamp":1709175579000},"page":"261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-5000","authenticated-orcid":false,"given":"Edoardo","family":"Agosti","sequence":"first","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-5545","authenticated-orcid":false,"given":"Marco","family":"Zeppieri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Antonietti","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-0639","authenticated-orcid":false,"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-1909","authenticated-orcid":false,"given":"Marco Maria","family":"Fontanella","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Panciani","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gazendam, A., Popovic, S., Parasu, N., and Ghert, M. (2023). Chondrosarcoma: A Clinical Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072506"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000509386","article-title":"Skull Base Chordomas and Chondrosarcomas","volume":"110","author":"Kremenevski","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_3","first-page":"42","article-title":"Comparison of chondrosarcoma cases: Current clinical situations among institutions","volume":"15","author":"Jami","year":"2021","journal-title":"Int. J. Health Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Palmisciano, P., Haider, A.S., Sabahi, M., Nwagwu, C.D., Bin Alamer, O., Scalia, G., Umana, G.E., Cohen-Gadol, A.A., El Ahmadieh, T.Y., and Yu, K. (2021). Primary Skull Base Chondrosarcomas: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13235960"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/000348941312201206","article-title":"Skull base chondrosarcomas: Surgical treatment and results","volume":"122","author":"Sbaihat","year":"2013","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zaj\u0105c, A.E., Kope\u0107, S., Szostakowski, B., Spa\u0142ek, M.J., Fiedorowicz, M., Bylina, E., Filipowicz, P., Szumera-Cie\u0107kiewicz, A., Tysarowski, A., and Czarnecka, A.M. (2021). Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 13.","DOI":"10.3390\/cancers13102390"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"772263","DOI":"10.3389\/fonc.2021.772263","article-title":"Metabolic Pathways and Targets in Chondrosarcoma","volume":"11","author":"Micaily","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., and Tsuchiya, H. (2022). Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031096"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Systematic reviews and Meta-Analyses","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_10","unstructured":"(2023, July 19). The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. Available online: https:\/\/www.researchgate.net\/publication\/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","article-title":"Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study","volume":"150","author":"Duffaud","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cncr.25632","article-title":"A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-\u03b1 or -\u03b2: An Italian Sarcoma Group study","volume":"117","author":"Grignani","year":"2011","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-12-0358","article-title":"Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L\/TRAIL (dulanermin), a dual proapoptotic receptor (DR4\/DR5) agonist","volume":"11","author":"Subbiah","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","unstructured":"(2024, January 31). Cixutumumab and Temsirolimus for Patients with Bone and Soft-Tissue Sarcoma: A Multicentre, Open-Label, Phase 2 Trial\u2014PubMed. Available online: https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.unibs.it\/23477833\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group\/US and French National Cancer Institute Single-Arm Phase II Collaborative Study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bupathi, M., Hays, J.L., and Chen, J.L. (2017). Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188116"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.2147\/CMAR.S253201","article-title":"Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn about the Biological Behavior of Chondrosarcoma from a Two-Center Study","volume":"12","author":"Xie","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients with Advanced Chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0959-8049(03)00227-2","article-title":"Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines","volume":"39","author":"Tomek","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jor.20364","article-title":"2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells","volume":"25","author":"Fong","year":"2007","journal-title":"J. Orthop. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ejca.2009.11.002","article-title":"COX-2 expression in chondrosarcoma: A role for celecoxib treatment?","volume":"46","author":"Schrage","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-08-4801","article-title":"Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment","volume":"69","author":"Schrage","year":"2009","journal-title":"Cancer Res"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4143\/crt.2011.43.2.124","article-title":"Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines","volume":"43","author":"Cheong","year":"2011","journal-title":"Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00280-017-3377-7","article-title":"Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma","volume":"80","author":"Miladi","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/15384101.2023.2166195","article-title":"A nonsteroidal anti-inflammatory drug, zaltoprofen, inhibits the growth of extraskeletal chondrosarcoma cells by inducing PPAR\u03b3, p21, p27, and p53","volume":"22","author":"Higuchi","year":"2023","journal-title":"Cell Cycle"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Morioka, H., Takahashi, S., Araki, N., Sugiura, H., Ueda, T., Takahashi, M., Yonemoto, T., Hiraga, H., Hiruma, T., and Kunisada, T. (2016). Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2511-y"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_33","first-page":"191","article-title":"Trabectedin: The evidence for its place in therapy in the treatment of soft tissue sarcoma","volume":"4","author":"Thornton","year":"2009","journal-title":"Core \u00c9vid."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00003086-200204000-00011","article-title":"Pathologic neovascularization in cartilage tumors","volume":"397","author":"McGough","year":"2002","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0046-8177(00)80248-8","article-title":"Microvasculature and VEGF expression in cartilaginous tumors","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"664853","DOI":"10.3389\/fonc.2021.664853","article-title":"Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-017-1030-2","article-title":"Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma","volume":"34","author":"Jones","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis","volume":"116","author":"Paniagua","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gobin, B., Moriceau, G., Ory, B., Charrier, C., Brion, R., Blanchard, F., Redini, F., and Heymann, D. (2014). Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090795"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_43","first-page":"357027","article-title":"Imatinib: A Breakthrough of Targeted Therapy in Cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Traylor, J.I., Pernik, M.N., Plitt, A.R., Lim, M., and Garzon-Muvdi, T. (2021). Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence. Cancers, 13.","DOI":"10.3390\/cancers13102408"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11864-022-00951-7","article-title":"Systemic Therapy for Chondrosarcoma","volume":"23","author":"Rock","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00262-008-0557-7","article-title":"Chordoma and chondrosarcoma gene profile: Implications for immunotherapy","volume":"58","author":"Schwab","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/bph.14999","article-title":"Bone sarcomas in the immunotherapy era","volume":"178","author":"Heymann","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PAP.0b013e31827b654d","article-title":"Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors","volume":"20","author":"Schaap","year":"2013","journal-title":"Adv. Anat. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: Mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1724600818774464","article-title":"Expression of PD-L1\/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma","volume":"33","author":"Yang","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.jbo.2019.100271","article-title":"The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target","volume":"20","author":"Richert","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1265716","DOI":"10.1080\/2162402X.2016.1265716","article-title":"Description of the immune microenvironment of chondrosarcoma and contribution to progression","volume":"6","author":"Simard","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","article-title":"Oncogenic Activities of IDH1\/2 Mutations: From Epigenetics to Cellular Signaling","volume":"27","author":"Boulay","year":"2017","journal-title":"Trends Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Venneker, S., Kruisselbrink, A.B., Baranski, Z., Palubeckaite, I., Bruijn, I.H.B.-D., Oosting, J., French, P.J., Danen, E.H.J., and Bov\u00e9e, J.V.M.G. (2020). Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 12.","DOI":"10.3390\/cancers12123589"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bereza, M., Dembi\u0144ski, M., Zaj\u0105c, A.E., Pi\u0105tkowski, J., Dudzisz-\u015aled\u017a, M., Rutkowski, P., and Czarnecka, A.M. (2023). Epigenetic Abnormalities in Chondrosarcoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054539"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Patnaik, E., Madu, C., and Lu, Y. (2023). Epigenetic Modulators as Therapeutic Agents in Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914964"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"702360","DOI":"10.3389\/fphar.2021.702360","article-title":"Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy","volume":"12","author":"Xiao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","article-title":"Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation","volume":"38","author":"Kan","year":"2022","journal-title":"Trends Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1101\/gad.262816.115","article-title":"A YAP\/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis","volume":"29","author":"Moroishi","year":"2015","journal-title":"Genes Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"30094","DOI":"10.18632\/oncotarget.8979","article-title":"TAZ and YAP are frequently activated oncoproteins in sarcomas","volume":"7","author":"Fullenkamp","year":"2016","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","article-title":"Hippo\u2013YAP\/TAZ signalling in organ regeneration and regenerative medicine","volume":"20","author":"Moya","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kovar, H., Bierbaumer, L., and Radic-Sarikas, B. (2020). The YAP\/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. Cells, 9.","DOI":"10.3390\/cells9040972"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Salguero-Aranda, C., Olmedo-Pelayo, J., de \u00c1lava, E., Amaral, A.T., and D\u00edaz-Mart\u00edn, J. (2022). Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma. Cancers, 14.","DOI":"10.3390\/cancers14246211"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/3\/261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:41Z","timestamp":1760105201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/3\/261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jpm14030261"],"URL":"https:\/\/doi.org\/10.3390\/jpm14030261","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}